Bial company says it made a innovative treatment for pacientes with Parkinson PD-GBA gennetic

 

 

Bial's scientific director speaks of a “fundamental milestone in the clinicmal developent of BIA 28-6156". He is confident that this medicine “has the potential to become a revolutionary and innovative treatment” for patients with a confirmed diagnosis of PD-GBA. “It has a specific mechanism of action, potentially disease-modifying, with the ability to slow clinical motor progression”, adds Joerg Holenz.

If successful in the remaining phases, this new treatment for the second most common neurodegenerative disease – affecting more than 10 million people worldwide – could be the third medicine developed by the national pharmaceutical company, which employs 800 people and generated revenues of almost 340 million euros in 2023, after having launched Zebinix (epilepsy) in 2009 and Ongentys (Parkinson's) in 2016.

Joaquim Ferreira, professor of Neurology and Clinical Pharmacology at the Faculty of Medicine of the University of Lisbon, researcher and member of the Steering Committee of the activate study, highlights that this is “another step in the exceptional effort to advance treatment options” and that it “follows the remarkable success of the recruitment phase”, which included more than 230 patients genetically confirmed with PD-GBA in 85 centers in Europe and North America.

https://eco.sapo.pt/2025/01/07/bial-atinge-marco-fundamental-em-novo-medicamento-para-doenca-de-parkinson/